Introduction
Intestinal failure (IF) is defined as a critical reduction of the functional gut mass leading to the inability to maintain absorption of sufficient nutrients, water, and electrolytes, such that intravenous (IV) supplementation becomes necessary. [1] [2] [3] [4] [5] [6] [7] Multiple factors can lead to the development of IF, such as major intestinal resections, motility disorders, and impaired mucosal function. 2, 6, 8 In the months following a major resection of the small bowel (SB), physiologic adaptation mechanisms such as increased villous height and crypt depth as well as intestinal dilatation take place. In the majority of cases, these adaptive mechanisms will be sufficient to restore nutrition independency and IF will therefore be temporary in the majority of the patients. 3 In cases in which these adaptive mechanisms are insufficient, dependency on parenteral nutrition (PN) becomes irreversible and IF becomes chronic. In such circumstances, long-term PN is the standard of care. 1, 7 Although life-saving and life-prolonging, long-term PN is associated with many potential complications, one of them being intestinal failure-associated liver disease (IFALD). 2 Although the definition of IFALD is highly variable among studies, IFALD is usually recognized as a chronic cholestatic disorder in patients with IF requiring long-term PN, in the absence of other primary liver diseases 9, 10 IFALD can present different histologic features depending on the age of the patient. Infants and young children usually have predominant cholestatic features on liver biopsy, while in adults IFALD is distinguished by the presence of steatosis, cholestasis, ductopenia, as well as perivenular and portal fibrosis. [11] [12] [13] Given the lack of a standardized definition, the prevalence of IFALD among adult patients requiring long-term PN is highly variable (15%-40%) among studies. 12, [14] [15] [16] [17] Many factors may increase the risk of IFALD development in adults: long duration of PN, PN composition (soybean-based lipid emulsions, excessive carbohydrate, caloric, or lipid content), extreme short bowel syndrome (i.e., ࣘ50cm of residual SB), absence of intestinal continuity with the colon, SB bacterial overgrowth, poor enteral intake, repeated systemic infections, and persistent systemic inflammation. 8, 11, 14, 16, [18] [19] [20] [21] [22] [23] Progression of IFALD to end-stage liver disease is highly variable among published series, varying from 0%-50%. [15] [16] [17] 24, 25 Patients with cirrhosis related to PN usually have a poor prognosis, the majority dying within the year following initial bilirubin elevation. 15, 26 Intestinal transplantation (ITx) is now a well-established therapy for patients with irreversible IF and severe complications related to long-term PN, such as IFALD. 2 Currently, ITx is recommended for patients with 1 or more of the following complications: impending or overt liver failure, thrombosis of 2 or more central veins, 2 or more episodes of severe catheter-related infections requiring hospitalization per year, or frequent episodes of dehydration despite adequate IV supplementation. 1, 2 Evaluation of the severity of IFALD and the extent of liver fibrosis can be especially challenging. Abnormalities in biochemical liver tests can underestimate the severity of liver disease in patients with IFALD. 13, 27 Moreover, massive intestinal resection with consequent reduced portal venous return can prevent development of the usual stigmata of portal hypertension (HTN) and thus mask the presence of advanced liver fibrosis. 27 In 1 study, non-invasive measurement of liver fibrosis with transient elastography was not correlated with the extent of liver fibrosis assessed by liver biopsy in patients with IFALD. 28 Therefore, liver biopsy appears to be the only reliable way to assess liver fibrosis among ITx candidates with IFALD.
Currently, the prevalence and risk factors for advanced liver fibrosis at the time of ITx in adults with IFALD is not well established. Therefore, this study aims to establish the prevalence and risk factors for advanced liver fibrosis among adults undergoing ITx.
Materials and Methods

Study Subjects
A retrospective study was conducted including all adult ITx recipients who had an incidental liver biopsy at the time of ITx at The Mount Sinai Hospital, New York, NY, USA. The study period extended from January 1, 2000 until May 1, 2014. During this period, a liver biopsy was performed whenever possible during the surgery for ITx at this institution. The basis for liver biopsy as part of clinical care was to guide practice in patients with some degree of liver injury at the time of ITx, where liver replacement was not planned. Children (<18 years), patients not receiving PN at the time of ITx, retransplants, and patients without a liver biopsy at the time of ITx were excluded.
All liver biopsies were retrospectively reviewed by an experienced liver pathologist (MIF) blinded to the patient's characteristics and final diagnosis. Hematoxylin and eosin and trichrome-stained slides were reviewed. The Brunt classification was used to grade and stage the severity of steatohepatitis and fibrosis, respectively. 29 Advanced liver fibrosis was defined as stage 3 (perisinusoidal and portal fibrosis with bridging fibrosis) or stage 4 fibrosis (cirrhosis). 29 Baseline characteristics, laboratory values, and PN characteristics were recorded.
Given the de-identified nature of the data, the Institutional Review Board at the Mount Sinai Hospital deemed this study exempt under provisions of the Code of Federal Regulations 45 CFR 46.101.
Statistical Analysis
Statistical analysis was conducted using SAS/STAT software, version 9.4 of the SAS system for Windows (SAS Canada Inc., Canada, Toronto, Ontario). Continuous variables are expressed as mean ± standard deviation when normality assumption was met and as median (interquartile range [IQR] ) when the normality assumption was violated. All categoric variables are reported as proportions.
Univariate analyses, i.e., Wilcoxon test and χ 2 test, were used to identify potential predictors of advanced liver fibrosis at the time of ITx. Variables with a P value ࣘ0.2 in univariate analysis were considered for inclusion in the final logistic regression model. Finally, a stepwise selection process was used to select variables into the final logistic regression model for advanced liver fibrosis at the time of ITx. Age, race, and gender were included into the final logistic regression model regardless of their P value in the univariate analysis. A 2-sided P value ࣘ.05 was considered statistically significant.
Results
During the study period, a total of 84 adults received an ITx. Among them, 6 were retransplants, 2 were not receiving PN at the time of ITx, and 22 did not have a liver biopsy performed at the time of ITx and were thus excluded. One patient had primary sclerosing cholangitis in association with inflammatory bowel disease and was excluded from the analysis. No other patients had a history of chronic liver disease and serologies for viral and autoimmune hepatitis were negative in all patients. Therefore, 53 (63.1%) adult patients met the inclusion criteria and were analyzed.
Baseline characteristics of the patients are detailed in Table 1 . The mean age of the patients was 50.6 ± 10.9 years and the majority were female (32/53; 61.4%) and Caucasian PN characteristics and liver tests prior to ITx are also detailed in Table 1 . The median (IQR) duration of PN prior to ITx was 402 (529) days, with all of the patients receiving PN 7 days a week. The median (IQR) number of grams of dextrose, amino acids, and lipids were 4.6 (1.4), 1.2 (0.5), and 0.8 (0.4) g/kg/d, respectively, for a median (IQR) number of calories of 25.3 (7.6) cal/kg/d. Moreover, 43 patients (87.8%) maintained some per os intake before ITx. At the time of ITx, the median (IQR) alanine aminotransferase level was 81 (116) U/mL, and the median (IQR) aspartate aminotransferase (AST) level was 63 (84) U/mL. The median (IQR) total bilirubin, alkaline phosphatase, and γ -glutamyltransferase levels were 0.9 (4.6) mg/dL, 226 (178) U/L, and 109 (102) U/mL, respectively. A total of 14 (26.4%) patients had a total bilirubin level ࣙ3.0 mg/dL during ࣙ4 weeks before ITx. At the time of ITx, the median (IQR) serum albumin level value, international normalized ratio (INR), and platelet count were 3.3 (1.1) g/dL, 1.0 (0.2), and 191 (122) x 10 9 /L, respectively. A total of 16 patients had platelets <150 × 10 9 at the time of ITx. 
Finally, the median (IQR) model for end-stage liver disease (MELD) score at the time of ITx was 11.5 (7.7).
Among the 53 patients who underwent a liver biopsy at the time of ITx, a total of 13 (24.5%) patients had advanced liver fibrosis (Table 2, Figure 1 ). In these patients, 9 (16.9%) had stage 3 fibrosis, and 4 (7.6%) had stage 4 liver fibrosis according to the Brunt classification. In the majority (8 of 13; 61.5%) of these patients, the indication for ITx was IFALD, and 5 of 13 (38.5%) received a liver-containing allograft at the time of ITx.
More specifically, among the 6 patients in whom a liver was included in the allograft, the indication for ITx was IFALD in 4 (66.7%) patients. The cause of IF was massive intestinal resection as a consequence of mesenteric ischemia in 3 (50%) patients. The median (IQR) residual SB length in these patients was 44 (86.3) cm and the median (IQR) duration of PN prior to ITx was 881 (5400) days. The median (IQR) MELD score at the time of ITx was 15.5.
14 Two (33.3%) patients had ascites and 1 (16.7%) patient developed hepatic encephalopathy prior to ITx. All patients in whom a liver was included in the allograft had a prolonged bilirubin elevation, thrombocytopenia, or elevated MELD score. At the time of ITx, the liver biopsy showed advanced liver fibrosis in 5 (83.3%) patients (3 had stage 4 liver fibrosis and 2 had stage 3 liver fibrosis).
A total of 12 patients had at least 1 liver biopsy performed prior to ITx. The median (IQR) time elapsed between the liver biopsy performed before ITx and ITx was 191 (295.8) days. Four (33.3%) patients had liver fibrosis stage 1, 7 (58.3%) patients had liver fibrosis stage 2, and 1 (8.3%) patient had liver fibrosis stage 3 on the liver biopsy performed before ITx. In comparison with the liver biopsy performed before ITx, the stage of liver fibrosis at the time of ITx remained the same in 8 (66.7%) patients and increased by at least 1 stage in 4 (33.3%) patients (from stage 1 to stage 2 in 1 patient, from stage 2 to stage 3 in 2 patients, and from stage 1 to stage 3 in 1 patient). For the patient in whom the liver fibrosis increased by 2 stages, the time elapsed from the biopsy performed before ITx and ITx was 45 days. Furthermore, 9 patients had a liver biopsy performed after ITx. The median (IQR) time between ITx and the subsequent liver biopsy was 126 (342.5) days, typically at the time of ostomy closure. After ITx, liver fibrosis stage improved in 4 of 9 patients (44.4%) and remained stable over time in 5 patients (55.6%). In the 2 patients with stage 3 liver fibrosis at the time of ITx, the stage of liver fibrosis improved to stage 2 in 1 patient and to stage 1 in 1 patient after ITx. In the patient with stage 3 liver fibrosis at the time of ITx, the liver fibrosis stage improved to stage 2 after ITx. Finally, in the patient with stage 4 liver fibrosis at ITx, the liver fibrosis stage remained at stage 4, but the thickness of the fibrous septa was much improved after ITx.
In univariate analysis, the following baseline characteristics were identified as potential predictors of advanced liver fibrosis at the time of ITx: age, gender, SB residual length, PN duration, lipids in PN, AST level, total bilirubin level, total bilirubin ࣙ3.0 mg/dL during ࣙ4 weeks, serum albumin level, INR, and MELD score (Table 3 ). In multivariate analysis, only gender was identified as a predictor of advanced liver fibrosis at the time of ITx (Table 4) . In this study, male gender was identified as a protective factor against advanced liver fibrosis at the time of ITx (odds ratio [OR] 0.02, P value = .025). A total bilirubin elevation ࣙ3.0 mg/dL during ࣙ4 weeks prior to ITx was associated with an increased risk for having advanced liver fibrosis (OR 8.85) but did not reach statistical significance (P = value .055).
Discussion
To our knowledge, this is the first study to report on the prevalence and risk factors for advanced liver fibrosis at the time of ITx. Moreover, this is the first study to report liver biopsy findings at the time of ITx in patients receiving longterm PN. In previous studies of IFALD, the definition of advanced liver disease among patients receiving long-term PN was highly variable and was often based on abnormalities of the biochemical liver tests. [15] [16] [17] 24 However, as shown by Naini et al., the histologic severity of IFALD does not always correlate with the severity of the abnormalities of biomarkers of liver dysfunction. 13 Thus, the availability of liver biopsies for pathologic evaluation of liver fibrosis at the time of ITx provides important information regarding liver function in these patients. Moreover, liver biopsies included in this study were all retrospectively graded for the stage of fibrosis by an expert liver pathologist blinded to the patient's characteristics, using a standard and previously validated scoring system used to report liver fibrosis. 29 In this study, the majority (63.1%) of the ITx recipients had a liver biopsy performed at the time of ITx. Despite the fact that 34.7% (17/53) of the patients required ITx for IFALD, advanced liver fibrosis was diagnosed on the liver biopsy of only 13 (24.5%) patients at the time of ITx. Among them, the majority (9 of 53; 17.0%) had stage 3 liver fibrosis and only 4 patients (7.6%) had cirrhosis. In comparison, Cavicchi et al. reported rates of complicated IFALD of 41.5% (37/90 patients) after a median PN duration of 17 months. 16 In that study, the definition of complicated IFALD was based on liver test abnormalities, and patients with results suggestive of further liver disease problems underwent a liver biopsy. 16 Among the 37 patients meeting the definition for complicated IFALD, 17 (47.9%) had extensive liver fibrosis and 5 (13.5%) had cirrhosis on liver biopsy. 16 The lower prevalence of advanced liver fibrosis in our study can be explained by In our study, the median number of grams of lipid and dextrose and the median caloric content of PN were all in concordance with the most recent recommendations. 1, 7 These recent modifications in management of patients requiring long-term PN most likely also contributed to the lower prevalence of advanced liver fibrosis in our patients. Moreover, only 5 patients were listed for a combined liverintestine transplant, the median total bilirubin level and INR were within the normal range, and the median MELD score was 11.5, reflecting the fact that the majority of the patients included in our study went into ITx with relatively well-preserved liver function. In this study, gender was the only variable in multivariate analysis significantly associated with advanced liver fibrosis at the time of ITx. In fact, male gender was identified as a protective factor against the development of advanced liver fibrosis (OR 0.02; P = 0.025). In other words, female gender was associated with a 50-fold greater risk of advanced liver fibrosis in comparison with male gender in our study. This same association between gender and the risk of severe liver dysfunction was also reported by Salvino et al. 17 In their study, severe liver dysfunction was defined based on liver test abnormalities, and female gender was shown as being predictive of severe liver dysfunction. 17 As previously reported, adults requiring long-term PN supplementation develop specific histologic abnormalities in which steatosis predominates. 13 Although still controversial, postmenopausal females with non-alcoholic steatohepatitis have been shown to have greater severity of liver fibrosis. [30] [31] [32] In this study, menopausal status was not assessed, although the mean age of the cohort was 50.6 years, and we can therefore hypothesize that lower sex hormone levels might have contributed to the development of fibrosis in female patients.
Although previously reported as risk factors for liver dysfunction in patients requiring long-term PN, our study could not demonstrate an association between residual SB length or PN duration and the risk of advanced liver fibrosis at the time of ITx. 16, 24 Moreover, despite being previously reported as risk factors, no association was found in this study between dextrose, lipid, or caloric content of PN and the risk of advanced liver fibrosis. 16, 33, 34 In the current study, all patients were followed by an experienced intestinal rehabilitation and transplantation team. Therefore, all patients had minimization of lipid and optimization of dextrose and caloric content of their PN according to the most recently published guidelines. 1, 7 Improved management of patients requiring long-term PN might explain the fact that no association between advanced liver fibrosis and residual SB length, PN duration, and PN composition was found in this study. Our inability to demonstrate this association in the current study does not negate the compelling evidence emphasizing the importance of optimizing nutrition management of IF patients receiving PN.
The current study suggests a trend toward significance (OR 8.85; P = .055) in multivariate analysis for an association between a total bilirubin elevation ࣙ3.0 mg/dL during ࣙ4 weeks and advanced liver fibrosis at the time of ITx. Given its relatively small sample size, our study most likely lacked power to detect a significant association between a prolonged bilirubin elevation and advanced liver fibrosis at the time of ITx. Despite this, the importance of the OR associated with prolonged elevation of bilirubin suggests that it is associated with advanced IFALD. Given its retrospective design, a causality link cannot be established between prolonged elevation of bilirubin and advanced liver fibrosis at the time of ITx. However, a prolonged elevation of bilirubin could be a marker of significant IFALD and should probably raise the suspicion of advanced liver fibrosis.
As demonstrated in previous studies, our study confirmed that successful isolated ITx without liver replacement has the potential to improve the stage of fibrosis after PN weaning. 16, 27, [35] [36] [37] Given the potential reversibility of liver fibrosis after isolated ITx, the decision to include the liver in the allograft should be weighed against the higher mortality on the waiting list for combined liver-ITx and the worse short-term outcome of patients undergoing such a transplantation. 21, 38, 39 Therefore, we believe that isolated ITx should be the preferred choice in all patients except in the presence of decompensated cirrhosis or portal HTN.
The limitations of this study are its retrospective nature, its small sample size, and the fact that it was conducted in only 1 center.
In summary, in our current study the prevalence of advanced liver fibrosis on liver biopsies performed at the time of ITx in patients requiring long-term PN was 24.5%. This study found an association between female gender and advanced liver fibrosis at the time of ITx. A trend towards significance was found between prolonged bilirubin elevation and advanced liver fibrosis. Our results suggest that patients with prolonged bilirubin elevation should undergo a liver biopsy prior to ITx in order to properly assess the degree of liver fibrosis and guide the choice of allograft to be transplanted.
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